N-{3-chloro-4-[(3-fluorophenyl)methoxy]phenyl}-6-[5-({[2-methanesulfonyl(1,2-13C2)ethyl]amino}methyl)furan-2-yl]quinazolin-4-amine

• ChemBase编号: 172223
• 分子式: C29H26ClFN4O4S
• 平均质量: 584.03626177
• 单一同位素质量: 583.1384768
• SMILES: c1c(cc2c(c1)ncnc2Nc1ccc(c(c1)Cl)OCc1cccc(c1)F)c1oc(cc1)C[15NH][13CH2][13CH2]S(=O)(=O)C
• Canonical SMILES: Fc1cccc(c1)COc1ccc(cc1Cl)Nc1ncnc2c1cc(cc2)c1ccc(o1)C[15NH][13CH2][13CH2]S(=O)(=O)C
• InChI: InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)/i11+1,12+1,32+1
• InChIKey: BCFGMOOMADDAQU-GROHAHKRSA-N

名称和登记号

名称

• IUPAC标准名: N-{3-chloro-4-[(3-fluorophenyl)methoxy]phenyl}-6-[5-({[2-methanesulfonyl(1,2-^1^3C₂)ethyl]amino}methyl)furan-2-yl]quinazolin-4-amine
• IUPAC传统名: N-{3-chloro-4-[(3-fluorophenyl)methoxy]phenyl}-6-[5-({[2-methanesulfonyl(1,2-^1^3C₂)ethyl]amino}methyl)furan-2-yl]quinazolin-4-amine
• 别名: N-[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-quinazolinamine-13C2,15N; GSK 572016-13C2,15N; GW 572016-13C2,15N; GW 572016X-13C2,15N; Lapatinib-13C2,15N

登记号

• PubChem SID: 164228133
• PubChem CID: 57347591

理论计算性质

• Acid pKa: 15.986492
• 质子受体: 7
• 质子供体: 2
• LogD (pH = 5.5): 2.9310408
• LogD (pH = 7.4): 4.425011
• Log P: 4.638509
• 摩尔折射率: 152.4172 cm^3
• 极化性: 61.300476 Å^3
• 极化表面积: 106.35 Å^2
• 可自由旋转的化学键: 11
• 里宾斯基五规则: false

分子性质

理化性质

• 溶解度: DMSO
• 外观: Pale Yellow Solid
• 熔点: >195°C (dec.)

安全信息

• 保存条件: -20°C Freezer

详细说明

Toronto Research Chemicals - L175804

Labelled Lapatinib (L175800). Reversible dual inhibitor of ErbB1 and ErbB2 tyrosine kinases. Antineoplastic.

参考文献

• Kim, T.E., et al.: Drugs, 6, 886 (2003)
• Wood, E.R., et al.: Cancer Res., 64, 6652 (2003)
• Spector, N.L., et al.: J. Clin. Oncol., 23, 2502 (2003)